Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Revance Therapeutics, Inc. (RVNC) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Revance Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1479290.
Total stock buying since 2014: $2,018,650.
Total stock sales since 2014: $32,386,337.
Total stock option exercises since 2014: $1,728,171.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2024 | 30,000 | $209,400 | 32,997 | $160,024 | 0 | $0 |
| 2023 | 0 | $0 | 418,174 | $12,659,174 | 2,500 | $45,300 |
| 2022 | 0 | $0 | 11,000 | $297,803 | 0 | $0 |
| 2021 | 76,400 | $1,049,532 | 186,993 | $5,278,604 | 0 | $0 |
| 2020 | 0 | $0 | 132,476 | $3,444,109 | 0 | $0 |
| 2019 | 0 | $0 | 18,557 | $302,476 | 1,291 | $11,140 |
| 2018 | 3,150 | $98,358 | 94,312 | $3,028,055 | 74,054 | $494,548 |
| 2017 | 20,000 | $543,960 | 123,656 | $2,804,741 | 64,137 | $474,160 |
| 2016 | 0 | $0 | 43,000 | $807,046 | 18,665 | $108,191 |
| 2015 | 0 | $0 | 27,253 | $818,756 | 31,545 | $160,763 |
| 2014 | 6,980 | $117,400 | 129,213 | $2,785,549 | 77,708 | $434,069 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2024-11 | 0 | $0 | 3,908 | $16,296 | 0 | $0 |
| 2024-04 | 0 | $0 | 2,392 | $9,096 | 0 | $0 |
| 2024-03 | 30,000 | $209,400 | 26,697 | $134,632 | 0 | $0 |
| 2023-09 | 0 | $0 | 34,853 | $612,621 | 0 | $0 |
| 2023-08 | 0 | $0 | 26,279 | $593,143 | 0 | $0 |
| 2023-07 | 0 | $0 | 27,980 | $697,938 | 0 | $0 |
| 2023-06 | 0 | $0 | 41,980 | $1,283,686 | 2,500 | $45,300 |
| 2023-05 | 0 | $0 | 137,465 | $4,739,888 | 0 | $0 |
| 2023-04 | 0 | $0 | 9,603 | $308,736 | 0 | $0 |
| 2023-03 | 0 | $0 | 132,112 | $4,179,013 | 0 | $0 |
| 2023-02 | 0 | $0 | 3,201 | $110,754 | 0 | $0 |
| 2023-01 | 0 | $0 | 4,701 | $133,395 | 0 | $0 |
| 2022-09 | 0 | $0 | 11,000 | $297,803 | 0 | $0 |
| 2021-12 | 36,400 | $533,612 | 0 | $0 | 0 | $0 |
| 2021-11 | 40,000 | $515,920 | 0 | $0 | 0 | $0 |
| 2021-09 | 0 | $0 | 1,675 | $50,250 | 0 | $0 |
| 2021-08 | 0 | $0 | 9,364 | $246,657 | 0 | $0 |
| 2021-07 | 0 | $0 | 109,714 | $3,279,987 | 0 | $0 |
| 2021-04 | 0 | $0 | 2 | $56 | 0 | $0 |
| 2021-03 | 0 | $0 | 33,119 | $842,216 | 0 | $0 |
| 2021-02 | 0 | $0 | 33,119 | $859,438 | 0 | $0 |
| 2020-12 | 0 | $0 | 33,119 | $921,204 | 0 | $0 |
| 2020-11 | 0 | $0 | 33,119 | $789,888 | 0 | $0 |
| 2020-10 | 0 | $0 | 33,119 | $865,962 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-11-18 | Hollander David (CMO & Global Therapeutics Lead) | Sale | 3,908 | 4.17 | 16,296 |
| 2024-04-16 | Jordan Erica (Chief Commercial Officer) | Sale | 2,392 | 3.80 | 9,096 |
| 2024-03-18 | Moxie Dwight (CLO & GC) | Sale | 8,125 | 5.04 | 40,974 |
| 2024-03-18 | Sjuts Dustin S (President) | Sale | 9,211 | 5.04 | 46,451 |
| 2024-03-18 | Schilke Tobin (CFO) | Sale | 9,361 | 5.04 | 47,207 |
| 2024-03-06 | Foley Mark J (CEO) | Buy | 30,000 | 6.98 | 209,400 |
| 2023-09-06 | Moxie Dwight (SVP, GC & Secretary) | Sale | 11,000 | 17.06 | 187,704 |
| 2023-09-05 | Moxie Dwight (SVP, GC & Secretary) | Sale | 23,853 | 17.81 | 424,917 |
| 2023-08-03 | Foley Mark J (CEO) | Sale | 26,279 | 22.57 | 593,143 |
| 2023-07-03 | Schilke Tobin (CFO) | Sale | 1,701 | 25.04 | 42,593 |
| 2023-07-03 | Foley Mark J (CEO) | Sale | 26,279 | 24.94 | 655,345 |
| 2023-06-15 | Kolaja Carey Oconnor | Sale | 2,500 | 28.24 | 70,600 |
| 2023-06-15 | Kolaja Carey Oconnor | Option Ex | 2,500 | 18.12 | 45,300 |
| 2023-06-09 | Sjuts Dustin S (President) | Sale | 5,000 | 30.82 | 154,095 |
| 2023-06-09 | Foley Mark J (CEO) | Sale | 31,279 | 30.72 | 960,922 |
| 2023-06-02 | Schilke Tobin (CFO) | Sale | 500 | 31.00 | 15,500 |
| 2023-06-01 | Schilke Tobin (CFO) | Sale | 2,701 | 30.57 | 82,569 |
| 2023-05-15 | Moxie Dwight (SVP, GC & Secretary) | Sale | 21,401 | 34.55 | 739,340 |
| 2023-05-15 | Sjuts Dustin S (President) | Sale | 21,015 | 34.55 | 726,005 |
| 2023-05-15 | Schilke Tobin (CFO) | Sale | 21,401 | 34.55 | 739,340 |
| 2023-05-15 | Foley Mark J (CEO) | Sale | 70,447 | 34.55 | 2,433,732 |
| 2023-05-01 | Schilke Tobin (CFO) | Sale | 3,201 | 31.70 | 101,471 |
| 2023-04-03 | Schilke Tobin (CFO) | Sale | 6,402 | 32.15 | 205,824 |
| 2023-03-09 | Moxie Dwight (SVP, GC & Secretary) | Sale | 18,496 | 31.59 | 584,214 |
| 2023-03-09 | Sjuts Dustin S (President) | Sale | 21,508 | 31.59 | 679,351 |
| 2023-03-09 | Schilke Tobin (CFO) | Sale | 18,517 | 31.59 | 584,877 |
| 2023-03-09 | Foley Mark J (CEO) | Sale | 70,390 | 31.59 | 2,223,338 |
| 2023-03-01 | Schilke Tobin (CFO) | Sale | 3,201 | 33.50 | 107,233 |
| 2023-02-01 | Schilke Tobin (CFO) | Sale | 3,201 | 34.60 | 110,754 |
| 2023-01-20 | Schilke Tobin (CFO) | Sale | 1,000 | 31.00 | 31,000 |
| 2023-01-09 | Schilke Tobin (CFO) | Sale | 3,701 | 27.67 | 102,395 |
| 2022-09-14 | Moxie Dwight (SVP, GC & Secretary) | Sale | 11,000 | 27.07 | 297,803 |
| 2021-12-13 | Russell Angus C. | Buy | 6,400 | 15.74 | 100,742 |
| 2021-12-03 | Rankin Aubrey (President, Innovation & Tech) | Buy | 30,000 | 14.43 | 432,870 |
| 2021-11-29 | Foley Mark J (CEO) | Buy | 40,000 | 12.90 | 515,920 |
| 2021-09-27 | Moxie Dwight (SVP, GC & Secretary) | Sale | 1,675 | 30.00 | 50,250 |
| 2021-08-16 | Rankin Aubrey (President, Innovation & Tech) | Sale | 9,364 | 26.34 | 246,657 |
| 2021-07-28 | Rankin Aubrey (President, Innovation & Tech) | Sale | 54,332 | 30.07 | 1,634,034 |
| 2021-07-26 | Rankin Aubrey (President, Innovation & Tech) | Sale | 55,382 | 29.72 | 1,645,953 |
| 2021-04-05 | Rankin Aubrey (President, Innovation & Tech) | Sale | 2 | 28.28 | 56 |
| 2021-03-04 | Rankin Aubrey (President, Innovation & Tech) | Sale | 33,119 | 25.43 | 842,216 |
| 2021-02-01 | Rankin Aubrey (President, Innovation & Tech) | Sale | 33,119 | 25.95 | 859,438 |
| 2020-12-30 | Rankin Aubrey (President, Innovation & Tech) | Sale | 33,119 | 27.82 | 921,204 |
| 2020-11-30 | Rankin Aubrey (President, Innovation & Tech) | Sale | 33,119 | 23.85 | 789,888 |
| 2020-10-29 | Rankin Aubrey (President, Innovation & Tech) | Sale | 33,119 | 26.15 | 865,962 |
| 2020-09-28 | Rankin Aubrey (President, Innovation & Tech) | Sale | 33,119 | 26.18 | 867,055 |
| 2019-03-18 | Allouche Cyril (Principal Accounting Officer) | Sale | 498 | 15.48 | 7,709 |
| 2019-03-18 | Browne L Daniel (CEO and President) | Sale | 11,613 | 15.51 | 180,071 |
| 2019-03-14 | Joshi Abhay (Chief Operating Officer) | Option Ex | 666 | 4.20 | 2,797 |
| 2019-02-19 | Browne L Daniel (CEO and President) | Sale | 5,446 | 17.68 | 96,285 |
| 2019-01-22 | Allouche Cyril (Principal Accounting Officer) | Sale | 625 | 17.77 | 11,106 |
| 2019-01-22 | Allouche Cyril (Principal Accounting Officer) | Option Ex | 625 | 13.35 | 8,343 |
| 2019-01-03 | Allouche Cyril (Principal Accounting Officer) | Sale | 375 | 19.48 | 7,305 |
| 2018-11-20 | Allouche Cyril (Principal Accounting Officer) | Sale | 491 | 20.66 | 10,144 |
| 2018-11-09 | Allouche Cyril (Principal Accounting Officer) | Sale | 2,188 | 23.72 | 51,899 |
| 2018-11-09 | Allouche Cyril (Principal Accounting Officer) | Option Ex | 2,188 | 13.35 | 29,209 |
| 2018-07-06 | Allouche Cyril (Principal Financial Officer) | Sale | 393 | 28.35 | 11,141 |
| 2018-05-22 | Silvernail Lauren P (CFO & CBO) | Sale | 2,874 | 30.25 | 86,924 |
| 2018-03-22 | Silvernail Lauren P (CFO, CBO & Secretary) | Sale | 3,431 | 30.85 | 105,839 |
| 2018-03-21 | Joshi Abhay (Chief Operating Officer) | Option Ex | 666 | 2.55 | 1,698 |
| 2018-03-16 | Vickers Philip J. | Buy | 3,150 | 31.23 | 98,358 |
| 2018-03-16 | Browne L Daniel (CEO and President) | Sale | 5,452 | 31.43 | 171,345 |
| 2018-03-16 | Browne L Daniel (CEO and President) | Option Ex | 20,000 | 2.55 | 51,000 |
| 2018-03-16 | Gardner Phyllis | Sale | 5,333 | 31.51 | 168,048 |
| 2018-03-16 | Gardner Phyllis | Option Ex | 5,333 | 2.55 | 13,599 |
| 2018-03-15 | Browne L Daniel (CEO and President) | Sale | 1,000 | 32.80 | 32,800 |
| 2018-03-13 | Silvernail Lauren P (CFO, CBO & Secretary) | Sale | 25,867 | 34.50 | 892,411 |
| 2018-03-13 | Silvernail Lauren P (CFO, CBO & Secretary) | Option Ex | 25,867 | 8.70 | 225,042 |
| 2018-03-09 | Silvernail Lauren P (CFO, CBO & Secretary) | Sale | 10,000 | 32.50 | 325,000 |
| 2018-03-09 | Silvernail Lauren P (CFO, CBO & Secretary) | Option Ex | 10,000 | 8.70 | 87,000 |
| 2018-03-07 | Browne L Daniel (CEO and President) | Sale | 27,283 | 31.43 | 857,504 |
| 2018-03-07 | Silvernail Lauren P (CFO, CBO & Secretary) | Sale | 10,000 | 31.50 | 315,000 |
| 2018-03-07 | Silvernail Lauren P (CFO, CBO & Secretary) | Option Ex | 10,000 | 8.70 | 87,000 |
| 2017-12-26 | Silvernail Lauren P (CFO, CBO & Secretary) | Option Ex | 17,506 | 8.70 | 152,302 |
| 2017-11-22 | Browne L Daniel (CEO and President) | Sale | 7,600 | 24.94 | 189,566 |
| 2017-11-07 | Foley Mark J (Director) | Buy | 20,000 | 27.20 | 543,960 |
| 2017-11-07 | Silvernail Lauren P (CFO, CBO & Secretary) | Sale | 10,000 | 26.83 | 268,270 |
| 2017-11-07 | Silvernail Lauren P (CFO, CBO & Secretary) | Option Ex | 10,000 | 8.70 | 87,000 |
| 2017-10-18 | Browne L Daniel (CEO and President) | Sale | 7,662 | 26.16 | 200,407 |
| 2017-10-12 | Silvernail Lauren P (CFO, CBO & Secretary) | Sale | 11,164 | 26.67 | 297,755 |
| 2017-09-20 | Browne L Daniel (CEO and President) | Sale | 7,600 | 23.58 | 179,185 |
| 2017-08-23 | Browne L Daniel (CEO and President) | Sale | 22,800 | 22.77 | 519,042 |
| 2017-08-23 | Browne L Daniel (CEO and President) | Option Ex | 331 | 2.55 | 844 |
| 2017-06-12 | Browne L Daniel (CEO and President) | Option Ex | 8,300 | 2.55 | 21,165 |
| 2017-05-30 | Browne L Daniel (CEO and President) | Option Ex | 5,000 | 2.55 | 12,750 |
| 2017-05-26 | Silvernail Lauren P (CFO, CBO & Secretary) | Option Ex | 23,000 | 8.70 | 200,099 |
| 2017-05-24 | Browne L Daniel (CEO and President) | Sale | 19,713 | 20.35 | 401,100 |
| 2017-05-22 | Browne L Daniel (CEO and President) | Sale | 12,287 | 20.20 | 248,160 |
| 2017-05-22 | Silvernail Lauren P (CFO, CBO & Secretary) | Sale | 1,793 | 20.20 | 36,211 |
| 2017-02-22 | Browne L Daniel (CEO and President) | Sale | 11,037 | 20.63 | 227,649 |
| 2017-01-25 | Browne L Daniel (CEO and President) | Sale | 12,000 | 19.78 | 237,396 |
| 2016-12-28 | Browne L Daniel (CEO and President) | Sale | 12,000 | 20.94 | 251,256 |
| 2016-11-25 | Browne L Daniel (CEO and President) | Sale | 12,000 | 18.28 | 219,360 |
| 2016-10-26 | Browne L Daniel (CEO and President) | Sale | 12,000 | 14.85 | 178,200 |
| 2016-08-12 | Joshi Abhay (Chief Operating Officer) | Option Ex | 666 | 6.60 | 4,395 |
| 2016-06-13 | Ruegg Curtis (EVP, Technical Operations) | Sale | 1,000 | 18.25 | 18,250 |
| 2016-06-13 | Ruegg Curtis (EVP, Technical Operations) | Option Ex | 1,000 | 8.70 | 8,700 |
| 2016-05-09 | Ruegg Curtis (EVP, Technical Operations) | Sale | 1,000 | 16.18 | 16,180 |
| 2016-05-09 | Ruegg Curtis (EVP, Technical Operations) | Option Ex | 1,000 | 8.70 | 8,700 |
| 2016-04-11 | Ruegg Curtis (EVP, Technical Operations) | Sale | 1,000 | 19.11 | 19,110 |
| 2016-04-11 | Ruegg Curtis (EVP, Technical Operations) | Option Ex | 1,000 | 8.70 | 8,700 |
| 2016-03-07 | Ruegg Curtis (EVP, Technical Operations) | Sale | 1,000 | 20.43 | 20,430 |
| 2016-03-07 | Ruegg Curtis (EVP, Technical Operations) | Option Ex | 1,000 | 8.70 | 8,700 |
| 2016-02-12 | Byrnes Robert F (Director) | Option Ex | 10,999 | 3.90 | 42,896 |
| 2016-02-08 | Ruegg Curtis (EVP, Technical Operations) | Sale | 1,000 | 18.14 | 18,140 |
| 2016-02-08 | Ruegg Curtis (EVP, Technical Operations) | Option Ex | 1,000 | 8.70 | 8,700 |
| 2016-01-06 | Ruegg Curtis (EVP, Technical Operations) | Sale | 2,000 | 33.06 | 66,120 |
| 2016-01-06 | Ruegg Curtis (EVP, Technical Operations) | Option Ex | 2,000 | 8.70 | 17,400 |
| 2015-12-30 | Browne L Daniel (CEO and President) | Option Ex | 12,045 | 2.55 | 30,714 |
| 2015-11-17 | Bertolino Arthur Peter (EVP and Chief Medical Officer) | Sale | 7,753 | 39.33 | 304,925 |
| 2015-08-17 | Ruegg Curtis (EVP, Technical Operations) | Sale | 3,000 | 30.49 | 91,482 |
| 2015-08-17 | Ruegg Curtis (EVP, Technical Operations) | Option Ex | 3,000 | 8.70 | 26,099 |
| 2015-07-17 | Ruegg Curtis (EVP, Technical Operations) | Sale | 3,000 | 31.03 | 93,090 |
| 2015-07-17 | Ruegg Curtis (EVP, Technical Operations) | Option Ex | 3,000 | 7.65 | 22,950 |
| 2015-06-17 | Ruegg Curtis (EVP, Technical Operations) | Sale | 3,000 | 33.53 | 100,593 |
| 2015-06-17 | Ruegg Curtis (EVP, Technical Operations) | Option Ex | 3,000 | 6.60 | 19,800 |
| 2015-06-03 | Ruegg Curtis (EVP, Technical Operations) | Sale | 500 | 30.00 | 15,000 |
| 2015-06-03 | Ruegg Curtis (EVP, Technical Operations) | Option Ex | 500 | 6.60 | 3,300 |
| 2015-05-18 | Ruegg Curtis (EVP, Technical Operations) | Sale | 2,500 | 26.69 | 66,735 |
| 2015-05-18 | Ruegg Curtis (EVP, Technical Operations) | Option Ex | 2,500 | 6.60 | 16,500 |
| 2015-05-15 | Ruegg Curtis (EVP, Technical Operations) | Sale | 500 | 25.00 | 12,500 |
| 2015-05-15 | Ruegg Curtis (EVP, Technical Operations) | Option Ex | 500 | 6.60 | 3,300 |
| 2015-04-17 | Ruegg Curtis (EVP, Technical Operations) | Sale | 2,000 | 22.23 | 44,466 |
| 2015-04-17 | Ruegg Curtis (EVP, Technical Operations) | Option Ex | 2,000 | 6.60 | 13,200 |
| 2015-03-19 | Ruegg Curtis (EVP, Technical Operations) | Sale | 500 | 20.00 | 10,000 |
| 2015-03-19 | Ruegg Curtis (EVP, Technical Operations) | Option Ex | 500 | 6.60 | 3,300 |
| 2015-03-17 | Ruegg Curtis (EVP, Technical Operations) | Sale | 1,500 | 18.61 | 27,915 |
| 2015-03-17 | Ruegg Curtis (EVP, Technical Operations) | Option Ex | 1,500 | 6.60 | 9,900 |
| 2015-03-09 | Ruegg Curtis (EVP, Technical Operations) | Sale | 500 | 18.00 | 9,000 |
| 2015-03-09 | Ruegg Curtis (EVP, Technical Operations) | Option Ex | 500 | 6.60 | 3,300 |
| 2015-02-17 | Ruegg Curtis (EVP, Technical Operations) | Sale | 1,000 | 16.80 | 16,800 |
| 2015-02-17 | Ruegg Curtis (EVP, Technical Operations) | Option Ex | 1,000 | 4.58 | 4,575 |
| 2015-01-20 | Ruegg Curtis (EVP R&D and Tech Operations) | Sale | 1,000 | 17.25 | 17,250 |
| 2015-01-20 | Ruegg Curtis (EVP R&D and Tech Operations) | Option Ex | 1,000 | 2.55 | 2,550 |
| 2015-01-09 | Ruegg Curtis (EVP R&D and Tech Operations) | Sale | 500 | 18.00 | 9,000 |
| 2015-01-09 | Ruegg Curtis (EVP R&D and Tech Operations) | Option Ex | 500 | 2.55 | 1,275 |
| 2014-12-17 | Ruegg Curtis (EVP R&D and Tech Operations) | Sale | 1,000 | 16.45 | 16,450 |
| 2014-12-17 | Ruegg Curtis (EVP R&D and Tech Operations) | Option Ex | 1,000 | 2.55 | 2,550 |
| 2014-12-11 | Silvernail Lauren P (CFO, Secretary & EVP Corp Dev.) | Buy | 980 | 17.73 | 17,380 |
| 2014-12-09 | Ruegg Curtis (EVP R&D and Tech Operations) | Sale | 500 | 18.00 | 9,000 |
| 2014-12-09 | Ruegg Curtis (EVP R&D and Tech Operations) | Option Ex | 500 | 2.55 | 1,275 |
| 2014-11-28 | Browne L Daniel (CEO and President) | Buy | 6,000 | 16.67 | 100,020 |
| 2014-11-18 | Ruegg Curtis (EVP R&D and Tech Operations) | Sale | 1,000 | 16.00 | 16,000 |
| 2014-11-18 | Ruegg Curtis (EVP R&D and Tech Operations) | Option Ex | 1,000 | 2.55 | 2,550 |
| 2014-10-28 | Ruegg Curtis (EVP R&D and Tech Operations) | Sale | 500 | 20.00 | 10,000 |
| 2014-10-28 | Ruegg Curtis (EVP R&D and Tech Operations) | Option Ex | 500 | 2.55 | 1,275 |
| 2014-10-17 | Ruegg Curtis (EVP R&D and Tech Operations) | Sale | 1,500 | 18.54 | 27,814 |
| 2014-10-17 | Ruegg Curtis (EVP R&D and Tech Operations) | Option Ex | 1,500 | 2.55 | 3,824 |
| 2014-09-17 | Waugh Jacob (Chief Scientific Officer) | Sale | 97,713 | 21.02 | 2,053,536 |
| 2014-09-17 | Waugh Jacob (Chief Scientific Officer) | Option Ex | 69,380 | 5.91 | 410,035 |
| 2014-09-17 | Ruegg Curtis (EVP R&D and Tech Operations) | Sale | 2,000 | 20.54 | 41,074 |
| 2014-09-17 | Ruegg Curtis (EVP R&D and Tech Operations) | Option Ex | 1,162 | 2.55 | 2,963 |
| 2014-09-17 | Byrnes Robert F (Director) | Option Ex | 2,666 | 3.60 | 9,597 |
| 2014-08-18 | Waugh Jacob (Chief Scientific Officer) | Sale | 25,000 | 24.47 | 611,675 |
Insider trading activities including stock purchases, stock sales, and option exercises of RVNC listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Revance Therapeutics, Inc. (symbol RVNC, CIK number 1479290) see the Securities and Exchange Commission (SEC) website.